Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Two-way crossover bioequivalence study of alendronate sodium tablets in healthy, non-smoking male volunteers under fasted conditions.

Thudi NR, Gagnon S, Hussain S, Abolfathi Z, Singla A, Pai R, Kumar S, Monif T.

Arzneimittelforschung. 2009;59(10):521-5.

PMID:
19998580
2.

Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.

Perkins AC, Blackshaw PE, Hay PD, Lawes SC, Atherton CT, Dansereau RJ, Wagner LK, Schnell DJ, Spiller RC.

Clin Ther. 2008 May;30(5):834-44. doi: 10.1016/j.clinthera.2008.04.018.

PMID:
18555931
4.

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.

Clin Drug Investig. 2006;26(2):63-74.

PMID:
17163237
5.

In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations.

Almeida S, Almeida A, Filipe A, Penedo C, Rocha A, Lainesse A, Vallée F.

Arzneimittelforschung. 2006;56(2):84-9.

PMID:
16572922

Supplemental Content

Loading ...
Support Center